Evidence map›Paper›PMID 23796912›Full record

ReviewDrug discovery today2013

Chemical denaturation as a tool in the formulation optimization of biologics.

Ernesto Freire, Arne Schön, Burleigh M Hutchins, Richard K Brown

Abstract readReview
In one paragraph

Review in Drug discovery today, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Fluorescence-Based Protein Stability Monitoring-A Review.International journal of molecular sciences · 2024
    Review
  5. Ethanol Inhalation as a Method to Denature the Spike Protein of SARS-CoV-2.Advances in experimental medicine and biology · 2024
    Article
  6. Article
  7. Chemical Protein Unfolding - A Simple Cooperative Model.The journal of physical chemistry. B · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Machine learning reveals hidden stability code in protein native fluorescence.Computational and structural biotechnology journal · 2021
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ernesto FreireAVIA Biosystems, 775 East Falmouth Highway, Suite 193, East Falmouth, MA 02536, USA.
Arne Schön
Burleigh M Hutchins
Richard K Brown

Funding

An Instrument to Determine Protein Stability for Biologics Formulations TestingR44GM096751 · NIGMS · AVIA BIOSYSTEMS, LLC · PI BROWN, RICHARD KENNETH · 2012 to 2013
$1.3M
Development of an Instrument to Determine Protein Stability at any Desired TemperR43GM096751 · NIGMS · AVIA BIOSYSTEMS, LLC · PI BROWN, RICHARD KENNETH · 2011 to 2011
$135k
NIGMS NIH HHS R43 GM096751NIGMS NIH HHS R44 GM096751NIGMS NIH HHS R44 GM096751-02
6 · The paper itself

Abstract

Biologics have become the fastest growing segment in the pharmaceutical industry. As is the case with all proteins, biologics are susceptible to denature or to aggregate; conditions that, if present, preclude their use as pharmaceuticals. Identifying the solvent conditions that maximize their structural stability is crucial during development. Since the structural stability of a protein is susceptible to different chemical and physical conditions, the use of several complementary techniques can be expected to provide the best answers. Stability measurements that rely on temperature or chemical [urea or guanidine hydrochloride (GuHCl)] denaturation have been the preferred ones in research laboratories and together provide a thorough evaluation of protein stability. In this review, we will discuss chemical denaturation as a tool in the optimization of formulation conditions for biologics, and how chemical denaturation complements the role of thermal denaturation for this purpose.

Indexed as

Protein DenaturationAnimalsBiological ProductsChemistry, PharmaceuticalHumansBiological Products

Identifiers

PMID23796912
PMCPMC3809824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.